 |
 |
|
|
|
| Lapatinib Ditosylate |
 |
| N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl] quinazolin-4-amine Bis(4-methylbenzenesulfonate) monohydrate |
 |
| [388082-78-8] |
 |
Lapatinib is a promising new breast cancer medication. It is an oral therapy targeting intracellular components of a receptor known as ErbB2 and a second receptor, ErbB1, which have been implicated in the growth of various tumor types. Early tests have shown excellent results in treatment of breast cancer, and researchers hope to try Lapatinib on other solid tumor cancers.
|
 |
| Appearance: Yellow crystalline powder. |
| Industrial field |
pharmaceutical |
|
|
 |
|
|
|
|
|
 |
| There are no existing companies to distribute selected chemical product |
|
 |
|
|
|
